Skip to main content

Renalytix AI PLC (RNLX)

NASDAQ: RNLX · Delayed Price · USD
27.10
-0.30 (-1.10%)
Pre-market:Oct 22, 2021 7:34 AM EDT
27.40
1.45 (5.59%)
At close: Oct 21, 4:00 PM
Market Cap989.70M
Revenue (ttm)1.02M
Net Income (ttm)-8.19M
Shares Out36.12M
EPS (ttm)-0.80
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume164,701
Open26.32
Previous Close25.95
Day's Range25.04 - 27.83
52-Week Range10.31 - 35.71
Beta1.24
AnalystsBuy
Price Target38.00 (+38.7%)
Est. Earnings Daten/a

About RNLX

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record, and systems to generate a unique patient risk score. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products ...

IndustryHealth Care Technology
IPO DateJul 17, 2020
Employees8
Stock ExchangeNASDAQ
Ticker SymbolRNLX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for Renalytix AI stock is "Buy." The 12-month stock price forecast is 38.00, which is an increase of 38.69% from the latest price.

Price Target
$38.00
(38.69% upside)
Analyst Consensus: Buy

News

Renalytix Reports Full Year Fiscal 2021 Results

LONDON and SALT LAKE CITY, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX), (LSE: RENX) an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical man...

1 day ago - GlobeNewsWire

3 Great Stocks You Can Buy With $50 Right Now

You can pick up small pieces of these great businesses for next to nothing.

Other symbols:AMRSOCUL
2 days ago - The Motley Fool

Renalytix to Report Fourth Quarter and Full Year Fiscal 2021 Financial Results on October 21

LONDON and SALT LAKE CITY, Oct. 08, 2021 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the Company will release fourth quarter and full year fiscal 2021 financial results ...

2 weeks ago - GlobeNewsWire

Renalytix Launching KidneyIntelX in Veterans Health Administration Hospitals

Jed Fulk Appointed Vice President Sales, Government Accounts Jed Fulk Appointed Vice President Sales, Government Accounts

2 weeks ago - GlobeNewsWire

3 Growth Stocks Wall Street Thinks Could Rise 50% or More

Analyst estimates suggest these stocks can deliver eye-popping gains once the rest of the stock market views them in the same light.

Other symbols:NVTASOFI
2 weeks ago - The Motley Fool

Mount Sinai Initiates System-wide Scale-Up of Renalytix KidneyIntelX™ Enabled Health Care Model

Targeted testing run rate of 300 diabetic kidney disease patients per week in calendar Q4 2021 Targeted testing run rate of 300 diabetic kidney disease patients per week in calendar Q4 2021

1 month ago - GlobeNewsWire

3 High-Growth Healthcare Stocks to Buy in September

All three are rapidly expanding into their own corners of America's $4 trillion per year healthcare sector.

Other symbols:HIMSNARI
1 month ago - The Motley Fool

Renalytix to Present at the 2021 Wells Fargo Virtual Healthcare Conference

NEW YORK and SALT LAKE CITY, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Renalytix plc (LSE: RENX) (NASDAQ: RNLX) (“Renalytix” or the “Company”) today announced the company will be presenting at the upcoming 202...

1 month ago - GlobeNewsWire

Renalytix Appoints Daniel J. Levangie to its Board of Directors

Levangie brings extensive commercial operating experience to Renalytix, served on boards of Exact Sciences, Insulet Corporation and Hologic Levangie brings extensive commercial operating experience to R...

1 month ago - GlobeNewsWire

3 High-Growth Stocks That Could Soar by 30% or Better According to Wall Street

There's a stock on this list analysts think can climb by around 47%, as soon as more investors come around to their way of seeing things.

Other symbols:NARIRDFN
1 month ago - The Motley Fool

Payer Budget Impact Analysis Projects Significant Savings from KidneyIntelX™ Testing at Primary Care Level

Peer reviewed publication in Journal of Medical Economics supports payer coverage for early-stage risk assessment and care management in the primary care office Peer reviewed publication in Journal of M...

1 month ago - GlobeNewsWire

3 High-Growth Healthcare Stocks to Buy in August

These potential stock rockets are well worth the different risks they present.

Other symbols:AMRSNNOX
2 months ago - The Motley Fool

Renalytix to Present at the 41st Annual Canaccord Genuity Global Growth Conference

NEW YORK, July 26, 2021 (GLOBE NEWSWIRE) -- Renalytix plc (LSE: RENX) (NASDAQ: RNLX) (“Renalytix” or the “Company”) today announced the company will be presenting at the upcoming 41st Annual Canaccord G...

2 months ago - GlobeNewsWire

3 High-Growth Stocks Truly Headed for the Moon

Find out why these niche businesses keep growing by leaps and bounds.

Other symbols:EVERFSLY
3 months ago - The Motley Fool

3 Top Life Science Stocks to Buy on Sale Right Now

Shares of these overlooked gems could make investors very rich once the rest of the market notices their value.

Other symbols:AMRSOCUL
3 months ago - The Motley Fool

Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2021

NEW YORK, June 15, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX) (“Renalytix” or the “Company”) today reported financial results for the quarter and nine months ended March 31, 2021.

4 months ago - GlobeNewsWire

Renalytix to Report Financial Results for Fiscal Third Quarter 2021 and Provide Corporate Update

Announces Change of Auditor to Ernst & Young LLP Announces Change of Auditor to Ernst & Young LLP

4 months ago - GlobeNewsWire

Leadership Additions Announced to Support Expanding US Government and Healthcare Provider KidneyIntelX Deployment

Enabling expertise in sales, population health and value-driven care models Enabling expertise in sales, population health and value-driven care models

4 months ago - GlobeNewsWire

Utility Study Indicates KidneyIntelX Risk Assessment can Address Treatment Ambiguity in Primary Care

Clinicians affirm need for accurate early-stage diabetic kidney disease risk assessment to improve patient outcomes and reduce healthcare costs Clinicians affirm need for accurate early-stage diabetic k...

4 months ago - GlobeNewsWire

Atrium Health, Wake Forest Baptist Health, Wake Forest School of Medicine and Renalytix Partner to Advance Kidney Health

Partnership marks a long-term commitment to reducing impact of kidney disease in large populations via integration of earlier risk assessment paired with comprehensive disease management Partnership mar...

5 months ago - GlobeNewsWire

Kantaro's COVID-SeroKlir Antibody Test Named As A Finalist For Fast Company's 2021 World Changing Ideas Awards

NEW YORK, May 4, 2021 /PRNewswire/ -- Kantaro Biosciences, LLC, a joint venture between the Mount Sinai Health System and RenalytixAI (LSE: RENX) (NASDAQ: RNLX), announced today that COVID-SeroKlir, its...

Other symbols:TECH
5 months ago - PRNewsWire

Renalytix AI Stock Jumps After 10-Year US Government Contract For Kidney Disease Testing Services

Renalytix AI plc (NASDAQ: RNLX) stock is rising on the heels of a 10-year contract from the United States Government to provide KidneyIntelX early-stage kidney disease bioprognostic testing services. Th...

5 months ago - Benzinga

KidneyIntelX Demonstrates Performance and Informs Treatment Decisions in Multinational CANagliflozin CardioVAScular A...

Data from 1,325 CANVAS Participants with Baseline DKD Scored with KidneyIntelX Presented at International Society of Nephrology World Congress of Nephrology 2021 Data from 1,325 CANVAS Participants with...

6 months ago - GlobeNewsWire

RenalytixAI and Joslin Diabetes Center Build on Proprietary Kidney Biomarker Portfolio for KidneyIntelX Platform

Agreement provides RenalytixAI with exclusive option to access intellectual property surrounding a comprehensive panel of novel biomarkers in kidney disease Agreement provides RenalytixAI with exclusive...

6 months ago - GlobeNewsWire

Clinical Utility Study Demonstrates Primary Care Physicians Highly Likely to Order KidneyIntelX to Inform Care Decisions

Value of KidneyIntelX Testing Demonstrated by Data from 401 Physician Study Presented at National Kidney Foundation 2021 Spring Clinical Meetings Value of KidneyIntelX Testing Demonstrated by Data from ...

6 months ago - GlobeNewsWire